07:21 AM EDT, 10/07/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that data from its phase 3 open-label extension study showed that its drug Omvoh, or mirikizumab-mrkz, achieved sustained clinical, endoscopic and steroid-free remission over four years in patients with moderate to severely active ulcerative colitis.

After four years of treatment, the company said that 78% of patients in clinical remission at one year achieved corticosteroid-free long-term remission, while 78% sustained long-term clinical remission and 81% sustained endoscopic remission.

Meanwhile, the long-term safety profile was consistent with prior data, with no new safety signals observed, the company said.